Ansell (PD1A) AI Stock Analysis

Ansell

(Frankfurt:PD1A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Margin Expansion and Cash GenerationImproved margins combined with sharply stronger free cash flow indicate better earnings quality and operating execution. This gives Ansell greater capacity to fund strategic investment, support shareholder returns, and absorb industry volatility while maintaining a stronger profit base.

Negative Factors

Choppy Revenue TrajectoryRecent growth is encouraging, but the uneven multi-year revenue record suggests demand and execution have not been consistently upward. That variability makes future margin and cash-flow improvements more dependent on continued recovery in volumes and favorable segment performance.

Ansell (PD1A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.05B
Dividend Yield: 2.79%
Average Volume (3M): 657
Price to Earnings (P/E): 21.9
Beta (1Y): 0.63
Revenue Growth: -0.42%
EPS Growth: 95.14%
Country: Germany
Employees: 15,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Ansell Business Overview & Revenue Model

Company Description

Ansell Limited is a global enterprise that conceptualizes, innovates, and produces protective equipment for various industries across numerous regions, including Asia Pacific, Europe, the Middle East, Africa, the Americas, and the Caribbean. The comp...

Ansell Earnings Call Summary

Earnings Call Date:Aug 22, 2026(Q4-2026)|Next Earnings Date:Feb 21, 2027

Earnings Call SentimentPositive

The call presented a clear majority of positive operational and financial outcomes — double-digit EPS growth, higher margins, strong cash conversion, U.S. and Cleanroom-led sales momentum, recurring cost savings (APIP $50M) and improved balance sheet metrics. Management also acknowledged and proactively managed notable headwinds (Middle East cost inflation, U.S. tariffs, commodity volatility, FX hedge losses and non‑cash impairments), and provided a constructive FY'27 EPS guidance range of $1.58–$1.70 with assumptions of continued volume/price momentum and ~$9M FX tailwind. On balance the positives — strong execution, margin expansion, cash generation and concrete operational improvements — outweigh the transient and manageable risks cited.

Positive Updates

Top-line growth and second-half momentum

Adjusted net sales grew 5.7% for FY'26 (ex-FX and product exits). Second-half growth accelerated to 9.2%, driven by improving volume trends.

Negative Updates

Middle East crisis cost volatility and ongoing uncertainty

Middle East conflict caused raw material and cost inflation; management passed costs to customers to offset impacts but emphasized continued uncertainty and the need for flexible pricing going forward.

Company Guidance

Ansell guided adjusted EPS of $1.58–$1.70 for FY27 (FY26 adjusted EPS $1.486), implying ~6.4%–14.4% upside (midpoint ~$1.64, ≈10.3% growth), on assumptions of continued sales momentum from both volume and pricing, focus on higher‑margin markets/brands and ongoing commercial and operational excellence; management also factored in a $9m FX benefit versus FY25. They expect GPADE and margin improvement from mix and productivity, SG&A to be managed around prior‑year growth (~2.7%), lower net capex than FY26 ($48.6m) with targeted strategic investment, continuation of the on‑market buyback program, and a conservative funding profile (net debt/EBITDA target 1.5–2.5x, currently 1.3x) with $752m of cash and undrawn facilities — while noting macro uncertainty.

Ansell Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PD1A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:RMD	84Outperform	AUD 46.01B	20.92	25.14%	0.91%	1.54%	4.43%
AU:MVP	67Neutral	AUD 41.12M	65.18	1.13%	―	8.99%	450.00%
AU:NAN	57Neutral	AUD 906.48M	51.44	8.16%	―	2.59%	-13.36%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:CSX	50Neutral	AUD 35.72M	-29.22	-6.27%	―	0.29%	-148.39%
AU:TRJ	46Neutral	AUD 38.22M	-62.50	-0.62%	―	-3.05%	86.01%

* Healthcare Sector Average

Performance Comparison

DE:PD1A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PD1A	Ansell Limited	28.40	8.33	41.48%
AU:NAN	Nanosonics Limited	3.03	-1.47	-32.67%
AU:MVP	Medical Developments International Limited	0.36	-0.32	-46.32%
AU:TRJ	Trajan Group Holdings Ltd	0.25	-0.53	-67.95%
AU:CSX	CleanSpace Holdings Ltd.	0.45	-0.25	-35.71%
AU:RMD	Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh	35.51	-1.92	-5.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ansell AI Stock Analysis